Your session is about to expire
← Back to Search
Tebentafusp (IMCgp100) for Melanoma
Study Summary
This trial will test the safety and effectiveness of tebentafusp (IMCgp100) as a single agent and in combination with durvalumab (MEDI4736) and/or tremelimumab in patients with metastatic cutaneous melanoma who have progressed on prior PD-1 inhibitors.
- Melanoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a live vaccine for an infectious disease within the past 4 weeks before starting the study treatment.You are expected to live for at least 3 more months.You have tumors in your brain or spinal cord that are causing symptoms and have not been treated yet.You have taken steroids to treat cancer that has spread to your brain for more than 2 weeks before starting the study treatment.You have had serious allergic reactions to the medications used in the study before.You have a serious heart condition or your heart isn't working properly.You have a current autoimmune disease or have had one in the past.You have had lung problems in the past caused by previous treatments.It's okay if you have been using local steroids like eye drops, inhalers, or joint injections.
- Group 1: Arm 1
- Group 2: Arm 2
- Group 3: Arm 5
- Group 4: Arm 4
- Group 5: Arm 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the conditions that IMCgp100 is used to treat?
"IMCgp100 is not only useful in treating unresectable stage iii non-small cell lung cancer, but also in metastatic ureter urothelial carcinoma and other advanced directives."
At how many sites is this research being conducted?
"Patients are being enrolled at 14 different centres across America, with 3 major locations being Washington University in St. Louis, Missouri, the University of Chicago in Illinois and Duke University Cancer Center in Durham, North carolina."
Are there any positions available for participants in this research project?
"That is correct. The online information shows that this study, which was originally posted on November 1st, 2015, is still looking for patients. In total, they need 312 people to participate and there are 13 different recruitment sites."
Could you please tell us if there is prior history with IMCgp100 in medical research?
"At the moment, there are 347 clinical trials underway for IMCgp100. 51 of these active studies are in their third phase. Most of the research being conducted for IMCgp100 is based out of Cordoba, Texas; however, there are a total 13136 locations running trials for this medication across the globe."
How many individuals are participating in this clinical trial?
"In order to run this study, 312 individuals that meet the pre-determined inclusion criteria are required. Candidates can enrol at sites such as Washington University in St. Louis or University of Chicago."
Is this the first time this type of experiment has been conducted?
"There are 347 ongoing studies involving IMCgp100 in 58 countries and 1334 cities. The first study, sponsored by AstraZeneca, completed Phase 2 drug approval in 2007 with 37 patients. Since then, 125 more trials have been completed."
Share this study with friends
Copy Link
Messenger